Calculus Capital is to waive initial fees on its new VCT until the end of the year, making it one of the most attractive in the current marketplace. Click here to download the Calculus VCT Brochure Most providers charge “promoter … Continued
Calculus Capital News
Calculus Capital has come out on top in the intense race for the Best EIS Investment Manager award at the fourth annual Growth Investor Awards, organised by Intelligent Partnership. Calculus was also named Best EIS Investment Manager in the 2016 awards. … Continued
Calculus Capital launches VCT fundraising – providing exposure to a diverse portfolio of entrepreneurial growth companies Calculus Capital has launched a £10 million fundraising for the Calculus VCT, which aims to deliver investors an annual dividend of 4.5% and capital growth. … Continued
Calculus Capital has led a £6m funding round in Arecor, the UK-based biopharmaceutical formulation company, to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The funding also involved Albion Capital and Downing Ventures, with BioScience Managers Limited advising … Continued
John Glencross was asked by BBC Newsnight to comment on the position for investors during the ongoing Brexit negotiations. To watch the short clip please see below.
London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued
CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such … Continued
The Enterprise Investment Scheme Association (EISA) has launched a new membership programme specifically aimed at Financial Planners and Regulated Advisers. And its FREE! Called the Financial Planning Programme, EISA aims to provide all individuals in the financial planning community with a … Continued
The Bioindustry Association held an informative webinar chaired by Calculus Capital Chief Executive John Glencross with panellists Michael Kipping- Innovation Lead at Innovate UK, Oliver Sexton- Investment Director at UK Innovation & Science Seed Fund and Kaivan Faria- Investment Analyst at Newable, on the … Continued
John Glencross, CEO of Calculus Capital discusses in June’s issue of GB Investment Magazine the strength of the UK entrepreneurial economy and how the boost in popularity of VCTs as a complementary product to maxed out pensions, shows that the … Continued